Translate

Showing posts with label prostate cancer. Show all posts
Showing posts with label prostate cancer. Show all posts

No Multi-Billion Dollar Fab Needed with Harvard License for Bottom-Up Semiconductor Assembly, Versatile Nano-Wire Makes Memory, LEDs and More


In United States Patent 7,595,260, Harvard College (Cambridge, MA)  Hyman Professor of Chemistry Charles M. Lieber with Yi Cui, Xiangfeng Duan and Yu Huang reveal bottom-up assembly of nanoscale electronic and optoelectronic devices including LEDs. The researchers demonstrated the ability to assemble active devices in the absence of multi-billion dollar fabrication lines which is of critical importance to the semiconductor and photonic fields and which they believe "augers well for the immediate and longer-term advances."

Lieber, Cui, Duan and Huang believe that the broad range of nanowire (NW) materials now available and the clearly defined ability to control their electronic properties will make possible nanoscale LEDs that cover the entire visible and near infrared range (e.g., GaN NWs for blue color). Such nanoscale light sources might be useful in creating new types of highly parallel optical sensors and for optical inter-connects in nanoelectronics. Moreover, the assembly of doped NW building blocks clearly has great potential for creating many other types of electronic devices and possibly even lasers.

With its extensive expertise in nanowire technologies, the laboratory of Charles Lieber has developed a novel high-performance memory device. Nonvolatile crossbar switches are memory elements created by crossing semiconductor and metal nanowires. Results have already shown bistable switching between ON and OFF states with ON/OFF ratios comparable to conventional devices (>104) and a well-defined, stable threshold voltage. Bit sizes are smaller than 20 nm by 20 nm, allowing for extremely high memory densities. 

Additionally, writes times of less than 100 nanoseconds have been demonstrated. Fully addressable memory arrays have been created exhibiting no cross-talk between individual elements, minimal degradation after thousands of cycles, and long memory retention times. In addition to operation on conventional substrates, the technology has been demonstrated on flexible plastic substrates, possibly allowing for low-cost manufacturing methods to be utilized for the creation of high-density, high-speed, stable and robust memory. The technology is available for licensing from the Harvard Office of Technology Development.

The microelectronics industry's continued success with scaling devices faces a number of physical limitations using current materials and device configurations. As demand surges for portable, high-density, low-cost memory, new technologies become increasingly attractive compared to the billion-dollar manufacturing requirements for conventional silicon. With revenues already in the tens of billions, memory for consumer electronics and PCs is a rapidly growing market demanding stable, robust, high-speed, and high-density technologies

The false-color scanning electron microscope image below is of Harvard zigzag nanowires in which the straight sections are separated by triangular joints and specific device functions are precisely localized at the kinked junctions in the nanowires


Image Credit: Harvard University, Bozhi Tian/Lieber Group


Taking nanomaterials to a new level of structural complexity,  Lieber's team has determined how to introduce kinks into arrow-straight nanowires, transforming them into zigzagging two- and three-dimensional structures with correspondingly advanced functions.  This work was described in October in a letter in the journal Nature Nanotechnology by scientists led by research assistant Bozhi Tian and Professor Lieber.

Among possible applications, the authors say, the new technology could foster a new nanoscale approach to detecting electrical currents in cells and tissues.  Nanowires for cancer detection have also been developed.  

Lieber and Tian’s approach involves the controlled introduction of triangular “stereocenters” – essentially, fixed 120-degree joints – into nanowires, structures that have previously been rigidly linear. These stereocenters, analogous to the chemical hubs found in many complex organic molecules, introduce kinks into 1-D nanostructures, transforming them into more complex forms. The researchers were able to introduce stereocenters as nanowires, which are self-assembled.

The researchers halted growth of the 1-D nanostructures for 15 seconds by removing key gaseous reactants from the chemical brew in which the process was taking place, replacing these reactants after joints had been introduced into the nanostructures. This approach resulted in a 40 percent yield of bent nanowires, which can then be purified to achieve higher yields. 

"The stereocenters appear as kinks, and the distance between kinks is completely controlled,” said Tian, a research assistant in Harvard’s Department of Chemistry and Chemical Biology. “Moreover, we demonstrated the generality of our approach through synthesis of 2-D silicon, germanium, and cadmium sulfide nanowire structures.”

The research by Lieber and Tian is the latest in the years-long efforts by scientists to control the composition and structure of nanowires during synthesis. Despite advances in these areas, the ability to control the design and growth of self-assembling nanostructures has been limited. Lieber and Tian’s work takes the formation of 2-D nanostructures a step further by enabling the introduction of electronic devices at the stereocenters.

“An important concept that emerged from these studies is that of introducing functionality at defined nanoscale points for the first time – in other words, nanodevices that can ‘self-label,’ ” Lieber said. “We illustrated this novel capability by the insertion of p–n diodes and field-effect transistors precisely at the stereocenters.”

Such self-labeled structures could open up the possibility of introducing nanoelectronics, photodetectors, or biological sensors into complex nanoscale structures.

Lieber and Tian’s co-authors are Ping Xie and Thomas J. Kempa of Harvard’s Department of Chemistry and Chemical Biology and David C. Bell of Harvard’s Center for Nanoscale Systems. Their work was funded by the National Institutes of Health, the McKnight Foundation, the MITRE Corp., and the National Science Foundation.

“We are very excited about the prospects this research opens up for nanotechnology,” has said Lieber, Mark Hyman Jr. Professor of Chemistry in Harvard’s Faculty of Arts and Sciences. “For example, our nanostructures make possible integration of active devices in nanoelectronic and photonic circuits, as well as totally new approaches for extra- and intracellular biological sensors. This latter area is one where we already have exciting new results, and one we believe can change the way much electrical recording in biology and medicine is carried out.”

In 2002, Professor Charles Lieber and his students have made nanowires that allowed Lieber's team to develop what is likely to be an important scientific tool, a coated wire capable of detecting low levels of a protein that marks the presence or recurrence of prostate cancer.




Nanotechnology Biobarcode System Detects "Undetectable" Levels of Prostate Specific Antigens

A team of Northwestern University researchers, using an extremely sensitive nanotechnology-based tool known as the biobarcode system, has detected previously undetectable levels of prostate-specific antigen (PSA) in patients who have undergone radical prostatectomy. This new assay, just one of many being developed by investigators at the Nanomaterials for Cancer Diagnostics and Therapeutics Center for Cancer Nanotechnology Excellence (Northwestern CCNE), is 300 times more sensitive than commercially available PSA tests.

The ability to easily and quickly detect very low levels of PSA may enable doctors to diagnose men with prostate cancer recurrence years earlier than is currently possible. Prostate cancer is the second leading cause of cancer death for men in the United States. (Only lung cancer is more deadly.) "We have defined a new zero for PSA," said Chad Mirkin, Ph.D., principal investigator of the Northwestern CCNE. "This level of sensitivity in detecting low concentrations of PSA will take the blinders off the medical community, especially when it comes to tracking residual disease." This study, which was led by Mirkin and C. Shad Thaxton, M.D., appears in the Proceedings of the National Academy of Sciences (PNAS).

"This new PSA assay may alter the management of patients who have been treated with surgery for prostate cancer," said William J. Catalona, M.D., director of the Clinical Prostate Cancer Program at Northwestern's Lurie Cancer Center. He was the first to demonstrate that the PSA test, a simple blood test, could be used as a screening tool for prostate cancer. "Studies have shown that postoperative radiation therapy given early to patients with adverse pathology, called adjuvant radiation, reduces the recurrence rate and improves survival," Catalona said. After the removal of the prostate gland, patients typically have PSA levels that are undetectable when measured using conventional diagnostic tools. "Because the 'nano-PSA assay' is more sensitive than the current commercially available PSA tests, it may allow physicians to target adjuvant radiation for patients destined to have a life-threatening tumor recurrence."

The study is an early indicator of how nanotechnology can be used to improve medical diagnostics and early cancer detection. In the case of prostate cancer recurrence following primary surgical treatment, patients with detectable but non-rising PSA levels could be reassured that their cancer will not recur. This reassurance potentially could be delivered much earlier than with conventional diagnostic tools. For patients with increasing levels of PSA, detected before conventional tools are able, doctors could diagnose a recurrence and intervene accordingly.

Furthermore, the effectiveness of post-operative treatment could be assessed by monitoring a patient's PSA levels. Tracking PSA levels early, before conventional tools are able, may allow doctors to validate treatments for recurrent cancer, such as radiation, hormone therapies and chemotherapies. The most effective will be able to keep down PSA levels.

"The first route to a new therapeutic is a good diagnostic tool, and that's what we have here," said Mirkin. "This bio-barcode assay, or a variant of it, could be a commercial tool in as little as 18 months. The technology is there. Now it's a business decision."

PSA is a protein produced by the cells of the prostate gland and found in the bloodstream. This pilot study looked at serum samples from 18 post-prostatectomy patients collected over the course of a number of years.

The researchers were able to reliably and accurately quantify PSA values at less than 0.1 nanograms per milliliter, the clinical limit of detection for commercial assays. The lower limit of detection for PSA using the bio-barcode assay is approximately 300 times lower than the lower limit of detection for commercial tests. The PSA measurements were used to classify the patients as either having no evidence of disease or having a relapse of disease. The Northwestern team is now conducting a similar retrospective study of 260 patients and eventually plans to do a large prospective study.

The ultra-sensitive technology is based on gold nanoparticle probes decorated with DNA and antibodies that can recognize and bind to PSA when present at extremely low levels in a blood sample. A magnetic microparticle, outfitted with a second antibody for PSA, also is used in the assay. When in solution, the antibody-functionalized particles "recognize" and bind to PSA, sandwiching the protein between the two particles.

The key is that attached to each tiny gold nanoparticle are hundreds of identical strands of DNA. Mirkin calls this "bar-code DNA" because they have designed it as a label specific to the PSA target. After the "particle-protein-particle" sandwich is removed magnetically from solution, the DNA is removed from the sandwich and read using a Verigene® ID system, a nanotechnology platform designed to detect and quantify DNA. The amount of PSA present is calculated based on the amount of bar-code DNA. For each molecule of captured PSA, hundreds of DNA strands are released, which is one of the ways the PSA signal is amplified.

This work, which is detailed in a paper titled, "Nanoparticle-based bio-barcode assay redefines 'undetectable' PSA and biochemical recurrence after radical prostatectomy," was supported by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. Investigators from the Innsbruck Medical University in Austria also participated in this study. An abstract of this paper is available at the journal's Web site.
Related Posts Plugin for WordPress, Blogger...